<!DOCTYPE html>
<html>
    <head>
        <meta charset="utf-8" />
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=1.0, maximum-scale=1.0, minimum-scale=1.0, user-scalable=no" />
        <title>Full STD Tx Guidelines</title>
        <link href="../jquery-mobile/jquery.mobile.theme-1.3.1.min.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.f.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.swatch.j.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/custom_arrow.css" rel="stylesheet" type="text/css"/>
        <link href="../jquery-mobile/jquery.mobile.structure-1.3.1.min.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/full.css" rel="stylesheet" type="text/css"/>
        <link href="../assets/css/recreated_tables.css" rel="stylesheet" type="text/css"/>
        <script src="../jquery-mobile/jquery-1.9.1.min.js" type="text/javascript"></script>
        <script src="../../jquery-customization.js" type="text/javascript"></script>
        <script src="../jquery-mobile/jquery.mobile-1.3.1.min.js" type="text/javascript"></script>
        <script src="../../cordova-2.7.0.js" type="text/javascript" charset="utf-8"></script>
        <script src="../assets/js/metrics.js" type="text/javascript" charset="utf-8"></script>
    </head>
    <body onload="onLoad()">
        <!-- Start of page -->
        <div data-role="page" id="g321" data-theme="d">
            <div data-role="header" data-id="guidelines-header" data-theme="j" data-position="fixed">
                <a href="lv-318.html" data-role="button" data-iconshadow="false" data-corners="false" data-theme="reset" data-transition="fade" class="back_button" role="button" aria-label="back"></a>
                <h1>Full STD Tx Guidelines</h1>
	            <a href="../menu.html"  rel="external" data-role="button" data-theme="reset" data-transition="fade" data-iconshadow="false" data-corners="false" class="menu_button ui-btn-right" role="button" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-318.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-318.html" >Human Papillomavirus (HPV) Infection</a><span class="carrot"> > </span>Prevention
            </div>
            </br><h2 class="sgc-1" id="sigil_toc_id_321">
 Prevention
</h2>
<p>
 Two HPV vaccines are licensed in the United States: a bivalent vaccine (Cervarix) containing HPV types 16 and 18 and a quadrivalent vaccine (Gardasil) vaccine containing HPV types 6, 11, 16, and 18. Both vaccines offer protection against the HPV types that cause 70% of cervical cancers (i.e., types 16 and 18), and the quadrivalent HPV vaccine also protects against the types that cause 90% of genital warts (i.e., types 6 and 11). Either vaccine can be administered to girls aged 11&ndash;12 years and can be administered to those as young as 9 years of age (15,16); girls and women ages 13&ndash;26 years who have not started or completed the vaccine series also should receive the vaccine. HPV vaccine is indicated for girls in this&nbsp;age group, because benefit is greatest if it is administered before the onset of sexual activity. The quadrivalent (Gardasil) HPV vaccine can also be used in males aged 9&ndash;26 years to prevent genital warts (17). Administering the vaccine to boys before the onset of sexual activity is optimal. Both HPV vaccines are administered as a 3-dose series of IM injections over a 6-month period, with the second and third doses given 1&ndash;2 and then 6 months after the first dose. Ideally, the same vaccine product should be used for the entire 3-dose series. HPV vaccine is available for eligible children and adolescents aged &lt;19 years through the Vaccines for Children (VFC) program (available by calling CDC INFO [800-232-4636]).
</p>
<p>
 Women who have received HPV vaccine should continue routine cervical cancer screening because 30% of cervical cancers are caused by HPV types other than 16 or 18. In the United States, the vaccines are not licensed or recommended for use in women &gt;26 years of age. No published data are available on the effectiveness, programmatic requirements, or cost-effectiveness of administering the HPV vaccine in STD clinic settings.
</p>

            </div>
            <script type="text/javascript">
                $('#g321').on('pageshow', function (event, ui) {
                    document.addEventListener("deviceready", function(){
                        trackFullGuidelinesPageView('321');
                                                },true);
                });
            </script>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

